FGFC1 Selectively Inhibits Erlotinib-Resistant Non-Small Cell Lung Cancer via Elevation of ROS Mediated by the EGFR/PI3K/Akt/mTOR Pathway

FGFC1 Selectively Inhibits Erlotinib-Resistant Non-Small Cell Lung Cancer via Elevation of ROS Mediated by the EGFR/PI3K/Akt/mTOR Pathway

Non-small cell lung cancer (NSCLC) is one of the most common malignancies in the world. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been used as a first-line treatment for patients harboring with EGFR mutations in advanced NSCLC. Nevertheless, the drug resistance aft...

Full description

Bibliographic Details
Main Authors: Shike Yan, Bing Zhang, Jingwen Feng, Haigang Wu, Namin Duan, Yamin Zhu, Yueliang Zhao, Shuang Shen, Kai Zhang, Wenhui Wu, Ning Liu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-01-01
Series:Frontiers in Pharmacology
Subjects:
FGFC1
non-small cell lung cancer
erlotinib-resistant
mitochondrial dysfunction
ROS
EGFR/PI3K/Akt/mTOR pathway
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.764699/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.764699/full

Similar Items